Allspring Global Investments Holdings LLC Cuts Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Allspring Global Investments Holdings LLC decreased its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 14.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 181,122 shares of the company's stock after selling 29,409 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.47% of Tarsus Pharmaceuticals worth $10,029,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Bleakley Financial Group LLC bought a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at approximately $323,000. Jennison Associates LLC increased its position in shares of Tarsus Pharmaceuticals by 14.8% during the 4th quarter. Jennison Associates LLC now owns 2,500,132 shares of the company's stock valued at $138,432,000 after purchasing an additional 321,552 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Tarsus Pharmaceuticals by 10.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,106 shares of the company's stock valued at $449,000 after purchasing an additional 789 shares during the last quarter. Baader Bank Aktiengesellschaft bought a new stake in Tarsus Pharmaceuticals during the 4th quarter valued at about $249,000. Finally, R Squared Ltd bought a new stake in Tarsus Pharmaceuticals during the 4th quarter valued at about $53,000. Institutional investors own 90.01% of the company's stock.

Tarsus Pharmaceuticals Stock Down 1.8 %

Shares of Tarsus Pharmaceuticals stock traded down $0.88 on Friday, reaching $47.84. The stock had a trading volume of 465,364 shares, compared to its average volume of 437,573. The company has a 50 day moving average price of $51.87 and a 200 day moving average price of $42.47. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals, Inc. has a 1 year low of $20.08 and a 1 year high of $57.28. The stock has a market capitalization of $1.83 billion, a P/E ratio of -12.56 and a beta of 1.01.

Analysts Set New Price Targets

A number of brokerages recently weighed in on TARS. Barclays lifted their price objective on shares of Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an "overweight" rating in a report on Monday, January 27th. The Goldman Sachs Group lifted their price objective on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a "neutral" rating in a report on Friday, November 15th. Guggenheim reissued a "buy" rating on shares of Tarsus Pharmaceuticals in a research report on Monday, February 10th. Finally, Oppenheimer raised their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $56.00.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.